Sterling Construction Co. (NASDAQ:STRL) on Monday reported a loss of $7.3 million in its fourth quarter. On a per-share basis, the Wilmington, Delaware-based company said it had a loss of 39 cents. The civil construction company posted revenue of $153.6 million in the period. For the year, the company reported that its loss narrowed to $9.8 million, or 54 cents per share. Revenue was reported as $672.2 million. On Monday shares of Sterling Construction Co. Inc. (NASDAQ:STRL) closed at $3.91. Company’s sales growth for last 5 years was 6.00% and EPS growth for next 5 years is recorded as 11.00%.
ArQule Inc. (NASDAQ:ARQL) on March 04, 2015, declared its financial results for the year and the fourth quarter ended December 31, 2014. The Company reported a net loss of $23,391,000 or $0.37 per share, for the year ended December 31, 2014, compared with a net loss of $24,600,000 or $0.39 per share, for the year ended December 31, 2013. ArQule Inc. (NASDAQ:ARQL) in last trading activity decreased -10.05% to close at $1.97. Company weekly performance is -19.92% while its quarterly performance stands at 57.60%. ArQule Inc. (NASDAQ:ARQL) is -21.20% away from its 52 week high.
Pfizer Inc. (NYSE:PFE) which has not yet filed for regulatory approval of its PCSK9 drug, said it expects outcomes data in a similar time frame. On Monday shares of Pfizer Inc. (NYSE:PFE) closed at $34.44. Company’s sales growth for last 5 years was 0.10% and EPS growth for next 5 years is recorded as 2.17%.
Ideal Power, Inc. (NASDAQ:IPWR) currently has a Zacks Rank #3 (Hold). Ideal Power, Inc. (NASDAQ:IPWR) has 21.01% insider ownership while its institutional ownership stands at 19.50%. In last trading activity company’s stock closed at $9.35.
On 9 March 2015, Alkermes plc (Nasdaq: ALKS) announced that it has entered into a definitive agreement to sell its manufacturing facility in Gainesville, GA, the manufacturing and royalty revenue associated with products manufactured at the facility and global rights to Meloxicam IV/IM to Recro Pharma, Inc. (Recro) (Nasdaq: REPH), a specialty pharmaceutical company. On last trading day Alkermes plc (NASDAQ:ALKS) increased 0.27% to close at $66.57. Its volatility for the week is 2.99% while volatility for the month is 3.50%. ALKS’s sales growth for past 5 years was 28.30% and its EPS growth for past 5 years was 12.90%. Alkermes plc (NASDAQ:ALKS) monthly performance is -9.17%.